 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178170] STImulatioN vs mediCal management for the Treatment of low back pain 
 
Version Number X 
Date 2022 April 6 
National Coordinating Clinical 
Investigator/Study Principal Investigator:               [INVESTIGATOR_847396], MD  
Study Co-Principal Investigator [INVESTIGATOR_847397](s) Up to [ADDRESS_1178171] 
Plano, TX [ZIP_CODE] 
Electronic Data Capture Software Oracle Clinical 
Core Laboratories  Sitka  
CIP Author of Current Version  
  XXXXXXXX 
 
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 2 of 48  
 
 
TABLE OF CONTENTS 
 
1.0 INTRODUCTION ................................................................................................................7  
1.1 Background and Rationale ......................................................................................................... 7  
 Background ............................................................................................................................ 7  
 Rationale for Conducting this Clinical Investigation ................................................................ 8  
2.0 CLINICAL INVESTIGATION OVERVIEW ......................................................................... 10  
2.1 Clinical Investigation Objective ................................................................................................ 10  
 Primary Objective(s) ............................................................................................................. 10  
2.2 Device(s) Used in the Clinical Investigation ............................................................................. 10  
 Name [CONTACT_26157](s) Under Investigation .......................................................................... 10  
 Indication for Use ................................................................................................................. 10  
 Description of the Device(s) Under Investigation .................................................................. 10  
 Description of the Non-Device Cohort .................................................................................. 10  
 Device Handling ................................................................................................................... 10  
3.0 CLINICAL INVESTIGATION DESIGN .............................................................................. 10  
3.1 Clinical Investigation Procedures and Follow-up Schedule ...................................................... 12  
3.2 Measures Taken to Avoid and Minimize Bias ........................................................................... 12  
3.3 Suspension or Early Termination of the Clinical Investigation .................................................. 12  
4.0 ENDPOINTS ..................................................................................................................... 13  
4.1 Primary Effectiveness Endpoint and Rationale......................................................................... 13  
4.2 Secondary Endpoints ............................................................................................................... 13  
4.3 Descriptive Endpoint(s) or Additional Data ............................................................................... [ADDRESS_1178172] Recruitment/Screening and Informed Consent ............................................................ [ADDRESS_1178173] Recruitment and Screening ..................................................................................... 14  
 Informed Consent ................................................................................................................. 14  
5.3 Eligibility Criteria ...................................................................................................................... 15  
 General Eligibility Criteria ..................................................................................................... 15  
 Inclusion Criteria .................................................................................................................. 15  
 Exclusion Criteria ................................................................................................................. 16  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178174] Withdrawal and Discontinuation .................................................................................. 18  
5.7 Number of Subjects ................................................................................................................. 20  
5.8 Total Expected Duration of the Clinical Investigation ............................................................... 20  
6.0 TREATMENT AND EVALUATION OF ENDPOINTS ........................................................ 20  
6.1 Enrollment ............................................................................................................................... 20  
6.2 Baseline ................................................................................................................................... 20  
 Baseline Clinical Assessments ............................................................................................. 20  
 Baseline Physical Function and Quality of Life Assessments ............................................... 20  
6.3 Randomization ......................................................................................................................... 21  
6.4 Conventional Medical Management (CMM arm) ...................................................................... [ADDRESS_1178175] Stimulation (interventional arm) ............................................................................ 21  
 Procedures Involved in the Use of the Device Under Investigation ....................................... 21  
 Trial Period ........................................................................................................................... 21  
 End of Trial Period ................................................................................................................ 21  
 Permanent System (if applicable) ......................................................................................... 22  
 Procedures Involved in the Use of the Device Under Investigation ....................................... 22  
 Permanent System Implementation ...................................................................................... 22  
6.6 Follow-up Assessments ........................................................................................................... 22  
 Follow-up for All Subjects (Site/Office/Telemedicine Visit or Telephone Call) ....................... 22  
 Patient Reported Outcome (PRO) Measures ........................................................................ 23  
 Follow-up Phone Call Visits .................................................................................................. 25  
 Crossover ............................................................................................................................. 25  
 Unscheduled Visits ............................................................................................................... 26  
 Schedule of Events .............................................................................................................. 26  
7.0 Adverse Events ................................................................................................................. 27  
7.1 Definition .................................................................................................................................. 27  
 Adverse Event ...................................................................................................................... 27  
 Serious Adverse Event ......................................................................................................... 27  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178176] death ............................................................ 29  
8.0 STATISTICAL CONSIDERATIONS .................................................................................. 29  
8.1 Analysis Populations ................................................................................................................ 29  
8.2 Statistical Analyses .................................................................................................................. 30  
 Primary Endpoint(s) Analyses .............................................................................................. 30  
 Secondary Endpoint(s) Analyses .......................................................................................... 30  
 Descriptive Endpoint(s) Analyses ......................................................................................... [ADDRESS_1178177] ACCESS TO SOURCE DATA/DOCUMENTS .................................................... 32  
10.0  QUALITY CONTROL AND QUALITY ASSURANCE ..................................................... 32  
10.1  Selection of Clinical Sites and Investigators ............................................................................. 32  
10.2  Clinical Investigation Finances and Agreements ...................................................................... 32  
10.3  CIP Amendments ..................................................................................................................... 32  
10.4  Training.................................................................................................................................... 32  
 Site Training ......................................................................................................................... 32  
10.5  Monitoring ................................................................................................................................ 33  
10.6  Deviations from CIP ................................................................................................................. 33  
10.7  Quality Assurance Audit ........................................................................................................... 34  
10.8  Sponsor Auditing ..................................................................................................................... 34  
10.9  Committees ............................................................................................................................. 34  
 Steering Committee .............................................................................................................. 34  
 Publications Committee ........................................................................................................ 34  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 5 of 48  
 
 Clinical Events Committee (CEC) ......................................................................................... [ADDRESS_1178178]/Medical Ethics Committee Review and Approval ........................... 37  
13.0  CLINICAL INVESTIGATION CONCLUSION ................................................................. 37  
14.0  PUBLICATION POLICY ................................................................................................ 38  
15.0  RISK ANALYSIS ............................................................................................................ 39  
15.1  Anticipated Clinical Benefits ..................................................................................................... 39  
15.2  Foreseeable Adverse Events and Anticipated Adverse Device Effects .................................... 39  
15.3  Residual Risks Associated with the Device Under Investigation, as Identified in the Risk 
Management Report / Risk Analysis Report ....................................................................................... 39  
15.4  Risks Associated with Participation in this Clinical Investigation .............................................. 39  
15.5  Steps Taken to Control or Mitigate Risks ................................................................................. 39  
15.6  Risk to Benefit Rationale .......................................................................................................... 40  
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 6 of 48  
 
COMPLIANCE STATEMENT:  
 
This clinical investigation will be conducted in accordance with this Clinical Investigation Plan, the 
Declaration of Helsinki, applicable Good Clinical Practices and regulations (e.g., US 21 CFR Part 50, 21 
CFR Part 56, 21 CFR Part 812 and OUS ISO14155:2020) and the appropriate local legislation(s). The 
most stringent requirements, guidelines or regulations must always be followed. The conduct of the 
clinical investigation will be approved by [CONTACT_144709] (IRB)/Ethics 
Committee (EC) of the respective investigational site and by [CONTACT_179190] (e.g., 
FDA, PMDA, MHRA, etc.). 
 
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178179] stimulation (SCS) is effective for relieving chronic intractable pain after failed back surgery 
syndrome (FBSS). Small studies have shown it to be effective in patients with predominant axial low 
back pain who are not candidates for surgery. However, larger randomized studies are needed. The 
purpose of this study is to evaluate the effectiveness of SCS stimulation compared with conventional 
medical management (CMM) in the treatment of chronic low back pain (CLBP) for patients who have not 
undergone and are not candidates for lumbar spi[INVESTIGATOR_79477]. 
This clinical investigation will be conducted in accordance with this CIP. All investigators involved in the 
conduct of the clinical investigation will be qualified by [CONTACT_8640], training, or experience to perform their 
tasks and this training will be documented appropriately. 
1.1 Background and Rationale 
 Background 
Low back pain affects over one billion people worldwide each year in all sociodemographic classes (1). It 
was the leading cause of years lived with disability in 2016 and was among the top 10 in 195 countries 
including the U.S. (2). While the majority of cases of low back pain resolve within six weeks, there are 35 
million adults in the U.S. (13.1%) who have chronic low back pain (CLBP) (3). Prevalence increases with 
age and is higher in women, current and former smokers, and obese individuals with BMI over 30 (3). 
There is a negative impact on physical function and quality of life, and patients with CLBP are three times 
more likely to have 10 or more healthcare visits per year (4).  
 
Most (95-98%) CLBP cases stem from a pathoanatomical diagnosis, but a minority (2-5%) stem from 
visceral causes such as cancer (3). Pathoanatomical diagnoses include spi[INVESTIGATOR_16078], spondylosis, 
spondylolisthesis, facet joint disease, disc herniation, and discogenic pain. While some of these are 
relatively straightforward to diagnose and have favorable treatment evidence, others require a complex 
diagnostic work-up. Additionally, most patients have more than one pain generator, making a singular 
and distinct pain-generating diagnosis difficult. 
 
There are several factors (psychological, economic, comorbidities) that impact the course of the 
condition and an individual’s response to treatment. It is likely that treatment success depends not only 
on reducing pain intensity, but also on improving functional capacity. In addition to the recognized 
psychological factors that impact the course of pain and response to treatment (e.g., pain 
catastrophizing, depression, anxiety), other factors such as smoking history, obesity, diabetes and 
financial/legal status also influence treatment outcomes.   
 
The widely accepted treatment algorithm for low back pain in an acute state begins with conservative 
care consisting of physiotherapy and medication optimization. Low back pain persisting for more than 
three months is considered chronic. Patients with CLBP are likely to be offered non-operative 
interventions such as anesthetic or steroid injections, radiofrequency ablation, and opi[INVESTIGATOR_2538]. Those 
with a clear anatomic pain generator may be offered surgery. Even with successful surgery at the correct 
anatomical level, there is inconsistent clinical effectiveness, and significant pain can persist from the 
original cause or from the post-surgical healing process (5-7). This phenomenon is commonly referred to 
as Failed Back Surgery Syndrome (FBSS). 
 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178180] reached 
the end of the treatment continuum. Unfortunately, this is despi[INVESTIGATOR_847398] a longer time to 
treatment predicts lower chance of therapeutic success, and poor outcomes of surgery in the absence of 
spi[INVESTIGATOR_158282] (8). 
 
Due to shortcomings in the current treatment algorithm, the economic burden of CLBP continues to rise. 
Recently, there has been a 300% increase in the number of low-back surgeries. The greatest proportion 
of overall health care expenditure in US hospi[INVESTIGATOR_847399], costing $12.8 billion in 2011.  
There was a 170% increase of primary lumbar fusions from 77,682 to 210,407 between 1998 and 2008 
(9). Up to 25% of diagnostic and therapeutic spi[INVESTIGATOR_847400]. Back pain is 
consistently ranked as one of the areas with the highest level of spending, in spi[INVESTIGATOR_847401], with $134.5 Billion spent alone in the US  in 2016 (10).For these reasons, providers, payers, 
and hospi[INVESTIGATOR_847402]-specific or surgery-specific factors play significant 
roles in postoperative outcomes (11). 
 Rationale for Conducting this Clinical Investigation 
Spi[INVESTIGATOR_54185] (SCS) has been used to treat chronic pain for more than 50 years and the 
mechanisms of its action are characterized in several publications (12-14). Recent advancements in 
neuromodulation, including BurstDRTM stimulation, have increased its overall effectiveness as a treatment 
modality for chronic pain (15, 16). To date, studies show that SCS is effective in the treatment of CLBP 
due to FBSS and is superior to conservative medical management and repeat surgery (17, 18).   
 
Previous neuromodulation trials in patients with low back pain suggest the potential for improved 
effectiveness compared to conventional medical management. The PROMISE randomized controlled trial 
(tonic SCS vs optimal medical management) for FBSS showed that 39.2% of patients achieved at least 
30% reduction in low back pain with SCS, compared to 12.0% in the medical management group (17). 
Tonic SCS brought about a decrease in Oswestry Disability Index of 12 points from baseline, and NRS 
scores for back and leg pain decreased by 2.0 and 1.6 vs baseline, respectively (17). A single-center study 
evaluating HF10 high-frequency SCS for axial low back pain with no previous spi[INVESTIGATOR_847403] 
75% of patients (15/20) had a reduction in VAS of more than 50% at six-month follow-up (19).  
 
In addition to its clinical effectiveness, SCS was found to be more cost-effective over the long term than 
operation or re-operation procedures (20). Considering the conflicting evidence on efficacy of other 
treatment modalities and the poor benefit-risk ratio of opi[INVESTIGATOR_2536], it is reasonable to consider 
using SCS earlier in the treatment continuum ahead of surgery and before initiating or escalating opi[INVESTIGATOR_847404]. 
 
The reimbursement landscape in the U.S. requires patients to try several conservative treatments 
(including opi[INVESTIGATOR_2438]) in a stepwise fashion in order of increasing invasiveness and cost before implantable 
technologies and surgery are covered. Moreover, the majority of commercial payors in the U.S. require a 
patient to have failed at least one spi[INVESTIGATOR_847405] a spi[INVESTIGATOR_847406]. 
Some patients must endure suboptimal pain control for months to years before targeted, aggressive 
treatments are considered. Functional capacity and psychological comorbidities such as depression and 
anxiety may continue to worsen until an effective intervention is used. 
 
BurstDR™ spi[INVESTIGATOR_847407] a waveform that mimics natural neural patterns and can deliver 
pain relief with reduced paresthesia or completely without paresthesia. It has been found to alter both 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 9 of 48  
 
sensory and emotional pathways in the brain, and achieved statistically superior pain relief compared to 
tonic SCS (21, 22). This prospective investigation is designed to evaluate the efficacy of BurstDRTM SCS 
compared with conventional medical management for improving pain and back-related physical function 
in patients suffering with chronic, refractory axial low back pain with a neuropathic component who have 
not had lumbar spi[INVESTIGATOR_847408].   
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 10 of 48  
 
2.0 CLINICAL INVESTIGATION OVERVIEW 
2.1 Clinical Investigation Objective 
 Primary Objective(s)  
The objective of this study is to evaluate the efficacy of BurstDRTM spi[INVESTIGATOR_54185], compared with 
conventional medical management, in improving pain and back pain-related physical function in patients 
suffering with chronic, refractory axial low back pain, who have not had lumbar spi[INVESTIGATOR_847409].  
2.2 Device(s) Used in the Clinical Investigation 
 Name [CONTACT_26157](s) Under Investigation 
BurstDRTM capable implantable pulse generators, along with relevant leads and accessories, will be used 
in this study. A detailed list of devices and system components can be referenced in CL1011119.  
 Indication for Use 
BurstDRTM capable devices are indicated as an aid in the management of chronic, intractable pain of the 
back, trunk and limbs, including unilateral or bilateral pain associated with the following: failed back 
surgery syndrome and intractable low back pain. 
 Description of the Device(s) Under Investigation 
Please refer to the country- and device-specific IFU for additional information regarding the devices used 
in this clinical investigation. 
 Description of the Non-Device Cohort 
SCS will be compared with conventional medical management (CMM) for CLBP. CMM consists of an 
array of therapi[INVESTIGATOR_44793], but not limited to structured physical therapy, medications, injections, and 
complementary and alternative medicine (e.g. acupuncture, massage therapy). 
 Device Handling  
The Sponsor requires all products to be stored according to the appropriate labeling and IFU as per 
standard practice at each center. 
3.0 CLINICAL INVESTIGATION DESIGN 
This is a prospective, multi-center, randomized, controlled clinical study with an optional crossover 
component. It is designed to evaluate the efficacy of BurstDRTM SCS in the treatment of chronic axial low 
back pain, compared to conventional medical management (CMM).   
  
Subjects will be followed in-clinic for required study visits at XXXXXXXX  months and via phone call or 
optional clinic visit at XXXXXXXX  -months.  Due to the individualized nature of study therapi[INVESTIGATOR_014], patient 
reported outcomes will be continually assesses and additional patient outreach conducted in order to 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 11 of 48  
 
determine if therapy adjustment(s) are warranted to optimize pain control. The primary endpoint will be 
assessed at the 6-month follow-up visit. Upon completion of the 6-month follow-up visit, subjects who are 
dissatisfied with therapy and receiving inadequate improvement with their treatment assignment will be 
allowed to cross-over to the other treatment arm, if desired.  
  
Up to XXXXXXXX  subjects will be randomized in the study XXXXXXXX .  
  
Subject enrollment is expected to be completed within XXXXXXXX ; subjects will be followed for 
XXXXXXXX  years. The total duration of the study is expected to be approximately XXXXXXXX  years, 
including enrollment, data collection from all subjects, and study close out.  
 
The Sponsor has designed this clinical investigation to involve as little pain, discomfort, fear, and any 
other foreseeable risk as possible for subjects. Refer to the Risks Analysis section of this clinical 
investigation plan for details. 
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178181] 
follow-up visits at XXXXXXXX , and XXXXXXXX  months. A detailed description of procedures/assessments 
performed at each follow-up visit is provided in Section 6.7. 
 
The Flow Chart and the Follow-up requirements of this clinical investigation are described below. 
 
Figure 3.1-1:  Clinical Investigation Flow Chart 
 
 XXXXXXXX  
3.2 Measures Taken to Avoid and Minimize Bias 
An independent Clinical Events Committee (CEC) will adjudicate all serious and non-serious device and 
procedure related adverse events, and all death events. 
An independent board-certified spi[INVESTIGATOR_847410] a medical monitor and evaluate each enrolled 
subject for suitability.  
3.3 Suspension or Early Termination of the Clinical Investigation 
While no formal statistical rule for early termination of the clinical investigation for insufficient 
effectiveness of the device under investigation is defined, the Sponsor reserves the right to discontinue 
the clinical investigation at any stage or reduce the follow-up period with suitable written notice to the 
investigator. Possible reason(s) may include, but are not limited to: 
 An oversight committee (e.g., Steering Committee) makes a recommendation to stop or terminate 
the clinical investigation (such as higher frequency of anticipated adverse device effects) 
    
Should the Sponsor discontinue the clinical investigation, sites will follow subjects per routine practice 
with device-related AEs reported to the Sponsor as per vigilance/commercial reporting requirements. The 
investigator shall return all clinical investigation materials to the Sponsor and provide a written statement 
to the IRB/EC (if applicable). All applicable clinical investigation documents shall be subject to the same 
retention policy as detailed in Section 11.[ADDRESS_1178182] of safety, the Sponsor will inform all other Principal Investigators. 
 
If suspension or premature termination occurs, the Principal Investigator [INVESTIGATOR_834517]/her site, if appropriate, and return subjects to their standard 
medical treatment. 
 
A Principal Investigator, IRB/EC, or regulatory authority may also suspend or prematurely terminate 
participation in the clinical investigation at the investigational site(s) for which they are responsible. The 
investigators will follow the requirements specified in the Clinical Trial Agreement.  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178183] is considered a responder for the primary endpoint if the following criterion is met: 
 Improvement in pain, defined as a ≥ 50% decrease on NRS  
4.2 Secondary Endpoints 
Selected secondary endpoints (e.g., change on ODI from baseline, % change in NRS from baseline) will 
be compared between the two treatment groups. Details are described in the Statistical Analysis Plan 
(SAP). 
4.3 Descriptive Endpoint(s) or Additional Data  
Descriptive endpoints include:  
 Proportion of patients who elect to cross-over after the primary endpoint 
 Change from baseline at each time point on the following: 
 ODI  
 PROMIS-29 questionnaire  
 Pain Catastrophizing Scale (PCS)  
 Pain-condition related medication usage  
 Exercise frequency  
 Healthcare resource utilization  
 Device programming and usage  
 Patient satisfaction with therapy  
 Patient Global Impression of Change (PGIC)  
 Serious device-related adverse events 
  
Responder analysis:  
 Proportion of subjects with ≥ 30% decrease on NRS  
 Proportion of subjects with ≥ 13% improvement, at least one category improvement or score ≤ 
20% on ODI  
  
 Proportion of subjects within 1 SD of population norm or reach MCID on PROMIS-29 domains 
 Proportion of subjects that are either clinically catastrophizing on PCS at baseline (PCS score ≥ 
30) and report a score of < 30 at follow up or report a 40% decrease in score at follow-up 
compared to baseline. 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178184] Recruitment/Screening and Informed Consent 
 Subject Recruitment and Screening 
Potential patients presenting at clinical sites will be fully informed about the clinical investigation, 
following the established Informed Consent process (described in Section 5.2.2). Once a duly dated and 
signed Informed Consent form is obtained, the clinical investigation-specific screening procedures may 
begin.  
Subjects must be screened for clinical investigation eligibility by a member of the site’s clinical 
investigation team previously trained to the CIP and will be recorded in a site-specific screening log. 
In case the subject does not meet all inclusion criteria or meets any of the exclusion criteria, the subject 
is considered a screening failure.  
Patients meeting general inclusion criteria and no exclusion criteria will be asked to sign an Informed 
Consent form if they wish to participate in the clinical investigation. 
Subject data will be collected following enrollment into the study. 
 
 Informed Consent 
The Investigator or his/her authorized designee (if applicable) will conduct the Informed Consent 
process, as required by [CONTACT_26137]’s IRB/EC. This process will include a 
verbal discussion with the patient on all aspects of the clinical investigation that are relevant to the 
patient’s decision to participate, such as details of clinical investigation procedures, anticipated benefits, 
and potential risks of clinical investigation participation. Sites must inform patients about their right to 
withdraw from the clinical investigation at any time and for any reason without sanction, penalty, or loss 
of benefits to which the patient is otherwise entitled. Withdrawal from the clinical investigation will not 
jeopardize their future medical care or relationship with the investigator.  
 
During the discussion, the Principal Investigator [INVESTIGATOR_022]/her authorized designee will avoid any improper 
influence on the patient and will respect patient’s legal rights. Financial incentives will not be given to 
patients. Patients may be compensated for time and travel directly related to the participation in the 
clinical investigation. The site shall provide the patient with the Informed Consent form written in a 
language that is understandable to the patient and that has been approved by [CONTACT_16018]’s IRB/EC. The 
patient shall have adequate time to review, ask questions, and consider participation. The Principal 
Investigator [INVESTIGATOR_022]/her authorized designee will make efforts to ensure that the patient understands the 
information provided. If the patient agrees to participate, they must sign and date the Informed Consent 
form, along with the person obtaining the consent prior to any clinical investigation-specific procedures. 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 15 of 48  
 
The site will file the signed original in the patient’s hospi[INVESTIGATOR_432599] a copy to the 
patient. 
 
Sites should report any failure to obtain informed consent from a patient to the Sponsor within 5 working 
days and to the reviewing center’s IRB/EC according to the IRB’s/ EC’s reporting requirements. 
 
If, during the clinical investigation, new information becomes available that can significantly affect a 
subject's future health and medical care, the Principal Investigator [INVESTIGATOR_022]/her authorized designee (if 
applicable) will provide this information to the subject. If relevant, sites will ask the subject to confirm their 
continuing informed consent in writing. 
[IP_ADDRESS] Special Circumstances for Informed Consent  
This clinical investigation excludes individuals unable to make the decision to participate in a clinical 
investigation on their own or who are unable to fully understand all aspects of the investigation that are 
relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a 
compromised position, expectation of benefits or fear of retaliatory response. This clinical investigation 
excludes individuals under the age of [ADDRESS_1178185] meet ALL general inclusion criteria to participate in the clinical 
investigation. If ANY general exclusion criteria are met, the patient is excluded from the clinical 
investigation and cannot be enrolled (recruitment failure). 
 
If any clinical and/or laboratory tests are required for patient screening and are not included in a site’s 
standard tests, they must be completed after written informed consent is obtained.  
 Inclusion Criteria 
1. Patient must be willing and able to provide written informed consent prior to any clinical 
investigation-related procedure. 
2. Age ≥ 18 years  
3. Patient has chronic (at least 6 months), refractory axial low back pain with a neuropathic 
component and is not a candidate for spi[INVESTIGATOR_79477] 
4. Patient has back pain for ≥ [ADDRESS_1178186] stimulation  
7. Low back pain ≥ 6 on Numerical Rating Scale 
8. Oswestry Disability Index score of ≥ 30% 
9. Willing and able to comply with the instructions for use, operate the study device, and comply with 
this Clinical Investigation Plan  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178187] 12 months that is clearly identified and 
is likely the cause of the CLBP, that can be addressed with surgery. 
2. Primary complaint of leg pain, or leg pain is greater than back pain 
3. Back pain is due to any of the following:  
 spi[INVESTIGATOR_847411] > 2 mm translation on radiographic imaging 
 visceral causes (e.g., endometriosis or fibroids)  
 vascular causes (e.g., aortic aneurysm)  
 spi[INVESTIGATOR_158394] (e.g., osteomyelitis)  
 inflammation or damage to the spi[INVESTIGATOR_1831] (e.g. arachnoiditis or syringomyelia) 
 tumor or spi[INVESTIGATOR_158308] 
 
4. Has widespread pain (e.g. fibromyalgia) or pain in other area(s), not intended to be treated in this 
study (e.g. neck pain, shoulder pain) 
5. Patient has seronegative spondyloarthropathy (e.g. rheumatoid, lupus, psoriatic) 
6. Neurological deficit (e.g. foot drop) 
7. Prior lumbar spi[INVESTIGATOR_847412] 
8. Patient has used a morphine equivalent daily dose of more than [ADDRESS_1178188] 30 days  
9. Patient is bed bound 
10. Patients with regular intake of systemic steroids (except inhaled steroids used to treat asthma) 
11. Imaging (MRI, CT, X-ray) findings within the last 12 months that contraindicates lead placement  
12. Known allergic reaction to implanted materials 
13. Severe scoliotic deformity (>11 degrees in thoracic or lumbar spi[INVESTIGATOR_050]) 
14. Patient has a history of, or existing intrathecal drug pump 
15. Patient has previous experience with neuromodulation devices, including a failed trial 
16. BMI > 40 
17. Patient is enrolled, or intends to participate, in another clinical drug and/or device study or registry 
that may interfere with the results of this study, as determined by [CONTACT_847438] 
18. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological 
conditions that, in the investigator’s opi[INVESTIGATOR_1649], could limit the subject’s ability to participate in the 
clinical investigation or to comply with follow-up requirements of the clinical investigation results. 
19. Failed psychological evaluation  
20. Suspi[INVESTIGATOR_847413], substance abuse, or drug-seeking behavior 
21. Patient demonstrated 2 or more Waddell’s signs of nonorganic behavior 
22. Patient is in current litigation for back pain/injury, or is currently receiving worker’s compensation 
23. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation 
follow-up period.  
 Female subjects of child-bearing potential must have a negative pregnancy test done 
within 7 days prior to enrollment/baseline visit per site standard test. 
5.[ADDRESS_1178189] Enrollment 
A patient is considered enrolled in the clinical investigation from the moment the patient provides written 
informed consent, has been confirmed to meet all inclusion criteria and none of the exclusion criteria, 
and eligibility has been confirmed by [CONTACT_7195]. 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178190] will 
continue in the study and be included in the analysis population. 
 Enrollment of Medicare Beneficiaries  
This clinical investigation will enroll Medicare beneficiaries and therefore conforms to all standards of 
Medicare coverage requirements. The Risks and Benefits section describes how all enrolled subjects, 
including Medicare beneficiaries, may be affected by [CONTACT_357028]. 
 
A portion of the subjects enrolled in the clinical investigation display characteristics consistent with the 
Medicare population based on age.  The clinical investigation results will be analyzed by [CONTACT_654] (< 65 years 
and ≥ 65 years) and compared to ensure that the outcomes are similar between the Medicare and non-
Medicare populations. 
 Historically Under-Represented Demographic Subgroups 
The Sponsor intends to implement FDA's guidance on sex-specific data in medical device clinical 
investigations to ensure adequate representation of women and other traditionally under-represented 
demographic subgroups in this clinical investigation.  As noted in the guidance, some barriers to 
participation of women and ethnic minorities in clinical investigations have traditionally been: 
 Lack of understanding about main obstacles to participation of such subgroups in clinical 
research  
 Inclusion/exclusion criteria potentially not needed to define the clinical investigation population 
may unintentionally exclude specific subgroups  
 Under diagnosis of disease etiologies and pathophysiology leading to under referral of 
demographic subgroups  
 Avoidance of specific subgroups by [CONTACT_404033]  
 Fear of fetal consequences (for female participants)  
 Family responsibilities limiting women's ability to commit time for follow-up requirements 
The Sponsor will take the following steps to ensure adequate representation of women and racial or 
ethnic minorities in this clinical investigation:  
 The Sponsor will provide training to investigational site personnel to ensure adequate 
representation of these demographic subgroups  
 The Sponsor will regularly review enrollment data to investigate whether there is under-
representation of these demographic subgroups  
 The Sponsor will regularly review withdrawal rates for under-represented subgroups and compare 
these rates with that in the overall clinical investigation population 
 As appropriate and necessary, the Sponsor will retrain sites on the importance of recruiting and 
retaining subjects in the clinical investigation 
 The Sponsor will approach sites without bias or consideration for specific demographic subgroups  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 18 of 48  
 
 The Sponsor will have informed consent materials in alternative languages and will work with 
sites and IRBs/ECs on recruitment materials  
5.[ADDRESS_1178191] meeting all general and screening eligibility criteria shall remain in the clinical investigation 
until completion of the required follow-up period; however, a subject’s participation in any clinical 
investigation is voluntary and the subject has the right to withdraw at any time without penalty or loss of 
benefit. Conceivable reasons for discontinuation may include, but not be limited to, the following: 
 Subject death 
 Subject voluntary withdrawal  
 Subject lost-to follow-up as described below  
 Subject’s follow-up is terminated according to Section 3.3 
 Subject’s neurostimulation system has been explanted 
    Subject becomes pregnant  
    Subject fails to comply with the protocol requirements 
 
Sites must notify the Sponsor of the reason(s) for subject discontinuation. Investigators must also report 
this to their respective IRB/EC as defined by [CONTACT_1385]’s procedure(s).  
 
No additional follow-up is required or data recorded from subjects once withdrawn from the clinical 
investigation, except for the status (deceased/alive). 
 
However, if a subject withdraws from the investigation due to problems related to the safety or 
performance of the study device, the investigator shall ask for the subject's permission to follow his/her 
status/condition outside of the clinical investigation. 
 
In case of subject withdrawal of consent, the site should make attempts to schedule the subject for a final 
clinical investigation visit. At this final follow-up visit, the subject will undergo the following assessments: 
 Review of adverse events 
 Administration of patient reported outcomes 
 
Lost-to-Follow-up  
If the subject misses two consecutive scheduled follow-up time points and the attempts at contact[CONTACT_361880], then the subject is considered lost-to-follow-up. Site personnel 
shall make all reasonable efforts to locate and communicate with the subject (and document these efforts 
in the source documents), including the following, at each contact [CONTACT_7206]: 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 19 of 48  
 
 A minimum of two telephone calls on different days over the specified follow-up windows to 
contact [CONTACT_150745], including date, time and 
initials of site personnel trying to make contact. 
 If these attempts are unsuccessful, the site should send a letter (certified if applicable) to the 
subject. 
 If a subject misses one or more non-consecutive follow-up contact [CONTACT_150746], it will be 
considered a missed visit. The subject may then return for subsequent visits. If the subject misses 
two consecutive time points and the above-mentioned attempts at communicating with the 
subject are unsuccessful, the subject will be considered lost-to-follow-up.  
 
Note:  Telephone contact [CONTACT_847439]. 
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 20 of 48  
 
5.7 Number of Subjects  
Approximately XXXXXXXX  subjects will be enrolled in the study. No site may contribute more than 
XXXXXXXX  % of the total sample. Assuming [ADDRESS_1178192] approximately XXXXXXXX  evaluable subjects sufficient for the primary endpoint 
analysis ( XXXXXXXX  %). 
5.8 Total Expected Duration of the Clinical Investigation 
This protocol assumes the following durations for key steps: approximately XXXXXXXX for the payor 
approval process, approximately XXXXXXXX  days for the trial period, approximately XXXXXXXX  months 
to schedule permanent implant procedure, and XXXXXXXX  months of follow-up. Based on these 
assumptions, each subject is expected to be enrolled in the study for approximately XXXXXXXX  months.  
 
This protocol assumes the following durations for key steps: XXXXXXXX  months for full enrollment, 
XXXXXXXX  months from the time the last subject receives a permanent implant to final follow-up, and 
XXXXXXXX  months for study closure. Based on these assumptions, the clinical investigation is expected 
to take XXXXXXXX  months. 
6.0 TREATMENT AND EVALUATION OF ENDPOINTS 
6.1 Enrollment 
During Enrollment, the following procedures will be performed: 
 Verification of written informed consent 
 Inclusion/Exclusion eligibility 
 Verification of eligibility by [CONTACT_605605] 
6.[ADDRESS_1178193]’s demographics, health status, and previous treatments for low back 
pain. The following data will be recorded at baseline: 
 Subject demographics including occupational status 
 Medical history (pain history and other interventions for pain management) 
 Pain condition-related medication use 
 Baseline Physical Function and Quality of Life Assessments  
Baseline data will be collected regarding physical function and quality of life. The following data will be 
recorded at baseline :  
 Numerical Rating Scale (NRS) for low back pain, and leg pain as applicable  
 PROMIS-29 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 21 of 48  
 
 painDetect questionnaire 
 Pain Catastrophizing scale (PCS)  
 Oswestry Disability Index (ODI) 
 Exercise frequency 
6.3 Randomization 
After enrollment has been completed, subjects will be randomized (3:2 ratio) to either the SCS arm or the 
CMM arm. Randomization will be stratified by [CONTACT_3725]. 
6.4 Conventional Medical Management (CMM arm) 
During the follow-up period, subjects in the CMM arm will receive supervised medical care, including 
medication optimization and supervised non-interventional therapy. Medication optimization should 
include use of non-steroidal anti-inflammatories and muscle relaxants, as appropriate. Supervised non-
interventional therapy may include, but is not limited to, physical therapy, chiropractic care, back school, 
cognitive behavioral therapy, and acupuncture. Interventional therapy such as injections and 
radiofrequency ablation, is also allowed.  Patient reported outcomes should be assessed after each 
patient interaction and therapy adjustment(s) (i.e. medication change) made as needed in order to 
optimize pain control.  
6.[ADDRESS_1178194] Stimulation (interventional arm) 
A successful trial, defined as 50% decrease in pain recorded on Numerical Rating Scale is required for a 
subject to receive a permanent implant. 
 Procedures Involved in the Use of the Device Under Investigation  
Descriptions of procedures associated with each device can be found in their respective IFU. 
 Trial Period 
Subjects randomized to receive spi[INVESTIGATOR_847414] a trial of the therapy. The trial 
period implementation should start no more than XXXXXXXX  days after the Baseline visit and should last 
at least 4 days. Only percutaneous leads may be used for the trial procedure. “On the table” trials and 
the use of paddle leads for the trial procedure are not allowed. 
The following data will be recorded at trial implementation: 
 Trial system details 
 Device programming 
 Device- and/or procedure related adverse events (if applicable)  
 All serious adverse events (if applicable) 
 Withdrawal (if applicable) 
 End of Trial Period 
The End of Trial Period data collection will occur after the trial period. At this visit, the following data will 
be recorded: 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 22 of 48  
 
 NRS for back pain, and leg pain as applicable 
 Patient reported pain relief 
 Device- and/or procedure related adverse events (if applicable)  
 All serious adverse events (if applicable) 
 Withdrawal (if applicable) 
 Permanent System (if applicable) 
Subjects reporting at least 50% improvement in back pain NRS and wish to proceed with the study will 
receive a permanent implant. The procedure will be performed according to the IFU. Permanent implant 
should be performed no later than [ADDRESS_1178195]’s 
spi[INVESTIGATOR_847415]. 
After programming, the subject will receive a patient programmer and will be instructed on how to use the 
system to relieve their pain. Subjects will be able to adjust the stimulation to ensure the best results. 
The following data will be recorded during permanent implementation: 
 Spi[INVESTIGATOR_847416] 
 Surgical procedure details 
 Device programming (if applicable) 
 Device- and/or procedure related adverse events (if applicable)  
 All serious adverse events (if applicable) 
 Withdrawal (if applicable) 
6.6 Follow-up Assessments  
 Follow-up for All Subjects (Site/Office/Telemedicine Visit or Telephone Call) 
Required follow-up visits will occur at XXXXXXXX  month (±14 days), and at XXXXXXXX (±30 days), and 
XXXXXXXX XXXXXXXX  -months (± XXXXXXXX days) after randomization or permanent implantation.  
Patient reported outcomes should be assessed after each follow-up visit and therapy adjustment(s)_(i.e. 
reprogramming) made as needed in order to optimize pain control.  Ongoing technical reprogramming 
assistance will be provided by [CONTACT_456].  
 
The following data will be collected at each visit: 
 Occupational status 
 Pain condition-related medication use 
 Patient-reported pain relief (PRPR) 
 NRS for back pain, and leg pain as applicable 
 PROMIS-29 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 23 of 48  
 
 Pain Catastrophizing scale (PCS)  
 Oswestry Disability Index (ODI)  
 Patient Global Impression of Change (PGIC) 
 Exercise frequency 
 Patient satisfaction with therapy 
 Device- and/or procedure related adverse events (if applicable)  
 System revision (if applicable) 
 Protocol deviation (if applicable) 
 Device programming (if applicable) 
 All serious adverse events (if applicable) 
 Withdrawal (if applicable) 
 
If a study participant is unable or unwilling to attend an in-person visit, the visit may be conducted 
remotely using telemedicine as provided by [CONTACT_5243]. Questionnaires may be administered during 
the remote visit. The Coordinator or designee must document the subject’s responses on the worksheet, 
note that the responses were collected via phone, save that document as source data, and enter the 
information in the EDC system. Alternately, questionnaires may be mailed to the participant in a return 
postage provided envelope. If this method is chosen, the Coordinator or designee should schedule a call 
with the subject to clearly explain the questionnaires and answer any questions the subject may have.  
 Patient Reported Outcome (PRO) Measures  
The Investigator, Coordinator or site designee will administer the patient-reported outcome 
questionnaires via paper for later transcription to EDC, or electronically. If the subject reported outcome 
questionnaire is provided to the subject electronically, the source data will be available in the EDC 
system for the site’s records. It is important the subject understands the meaning of all words and 
instructions in the questionnaires. The subject should be instructed to ask any questions about the 
questionnaires, if further explanation is needed. Once the questionnaires are completed, the Coordinator 
or designee will review for completeness to verify that all questions have been answered according to the 
directions provided. If the subject is unable to attend a follow up visit in person, questionnaires may be 
sent to the subject and returned to the site. The Coordinator or designee should schedule a call with the 
subject to clearly explain the questionnaires and answer any questions the subject may have. 
Alternatively, If the subject is unable to attend a follow up visit in person, the Investigator or designee 
may also schedule a phone call or telemedicine visit with the subject to review the questionnaires. The 
Coordinator or designee should document the subject’s responses on the worksheet, note that the 
responses were collected via phone, save that document as source data, and enter the information in the 
EDC system. 
 
 Patient Global Impression of Change (PGIC) 
 Patient-reported pain relief (PRPR) 
 Numerical Rating Scale (NRS)  
 PainDetect (PD-Q) 
 Oswestry Disability Index (ODI) 
 PROMIS-29 
 Pain Catastrophizing Scale (PCS) 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 24 of 48  
 
[IP_ADDRESS] Patient Global Impression of Change (PGIC) 
The PGIC is a categorical rating scale used to evaluate the subject’s impression of change in his/her 
condition since the beginning of the study treatment. The subject will be requested to rate their overall 
change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition 
on a seven-point categorical scale via an interview technique. The categories are as follows: 1- no 
change, 2- almost the same, 3 - a little better, 4 - somewhat better, 5-moderately better, 6 - better, and 7-
a great deal better. Although this tool does not specify the area of change (e.g., pain, function, quality of 
life, etc.), it allows for an overall integrated assessment from the prospective of the subject. PGIC values 
of [ADDRESS_1178196] with actual change (23, 24). 
[IP_ADDRESS] Patient-reported pain relief (PRPR) 
The PRPR asks a subject to state the percentage pain relief they receive from their treatment. The scale 
ranges from 0% = no relief to 100% = complete pain relief. 
[IP_ADDRESS] Numerical Rating Scale (NRS) 
The pain NRS consists of 1 question that will be asked by [CONTACT_421254]. Patients will be 
asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their average pain over the past 24 hours 
specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity 
[IP_ADDRESS] PainDETECT Questionnaire (PD-Q) 
The painDETECT (PD-Q) is a validated self-reported questionnaire that discriminates between 
neuropathic and nociceptive pain components in patients with chronic pain. The PD-Q is comprised of 
three sections:  gradation of pain (7 questions), pain course pattern (1 question), and radiating pain (1 
question). Each question addresses the quality of neuropathic pain symptoms and is scored individually. 
Gradation of pain questions are scored from 0-5. The pain course pattern question score ranges from -1 
to +1, and the radiating pain question score ranges from +2/0. The overall PD-Q score ranges from 38 to 
-1. The higher the score, the higher the likelihood of a neuropathic pain component. A score ≤ 12 
suggests that a neuropathic pain component is unlikely. Scores ≥ [ADDRESS_1178197] that the presence of a neuropathic pain 
component is unclear and requires further examination to ensure a proper diagnosis. The sensitivity of 
this tool was validated by [CONTACT_847440]. at 84% (25). 
[IP_ADDRESS] Oswestry Disability Index (ODI) 
The ODI is an index derived from the Oswestry Low Back Pain Questionnaire used by [CONTACT_847441] (26). The self-completed questionnaire contains ten 
topi[INVESTIGATOR_847417], lifting, ability to care for oneself, ability to walk, ability to sit, sexual 
function, ability to stand, social life, sleep quality, and ability to travel. Each topic category is followed by 
[ADDRESS_1178198]'s life relating to the topic. The subject 
checks the statement which most closely resembles their situation. Each question is scored on a scale of 
0–[ADDRESS_1178199] severe disability. The scores for all questions answered are summed, divided 
by [CONTACT_847442] a percentage. 
Zero is equated with no disability and 100 is the maximum disability possible. Five different levels of 
disability are defined within that range; minimal (0%-20%), moderate (21%-40%), severe (41%-60%), 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 25 of 48  
 
crippling (61%-80%), and bed bound or exaggerated symptoms (81-100%). A decrease of 13% or more 
on the 0%-100% scale demonstrates a meaningful, clinical improvement in disability (27).  
[IP_ADDRESS] Patient-Reported Outcome Measure Information System (PROMIS) 29 
The PROMIS-29 is a 29-item profile instrument developed in partnership with the National Institutes of 
Health (NIH) to estimate overall quality of life by [CONTACT_58833] [ADDRESS_1178200] activities of 
daily living: depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and 
social function. The final item is an 11-point pain intensity numerical rating scale (NRS). Subjects should 
read each item and check the one box that most closely represents their response. Each item is scored 
on a scale from 1-5 with total scores for each domain ranging from 4-20. Greater scores represent more 
of whatever concept is being measured (e.g., depression or physical function). Scoring tables have been 
provided in the measure manual. Raw domain scores are converted to t-scores with a mean of [ADDRESS_1178201] deviation of 10.  
[IP_ADDRESS] Pain Catastrophizing Scale (PCS) 
The PCS is a validated, 13-item scale that evaluates 3 domains of pain-related negative thoughts 
(rumination, magnification, and helplessness). Subjects rate how often they have the given thought from 
0 “not at all” to 4 “all the time”. The total score is a sum of all responses, ranging from 0-52. Each domain 
has a sub-scale score calculated as a sum of the constituent responses with ranges of 0-[ADDRESS_1178202] been evaluated to set 
scores expected in normal, non-chronic pain populations and changes in scores that are clinically 
meaningful to patients. A score of 13.87 is representative of a normal, healthy population (28). A total 
score of 30 or above indicates a patient is clinically catastrophizing. A 38-44% reduction in score 
represents a noticeable improvement to the patient (29).      
 Follow-up Phone Call Visits 
Follow-up phone call visits will occur at XXXXXXXX  and XXXXXXXX -months (± 30 days) after 
randomization or permanent implantation, whichever is more applicable. The following data will be 
collected at each visit: 
 
 Patient Global Impression of Change 
 Verbal pain rating scale for pain intensity (0-10 numerical rating scale administered verbally) 
 Device- and/or procedure related adverse events (if applicable)  
 All serious adverse events (if applicable) 
 Programming details (if applicable) 
 
 Crossover 
Crossover prior to the study primary endpoint is not allowed. To ensure valid analysis of all endpoints, 
investigators and coordinators must make concerted efforts to prevent crossover from CMM to SCS prior 
to completing the 6-month visit. If a subject is unwilling to complete the assigned treatment, they should 
be withdrawn. Upon completion of the 6-month primary endpoint visit, a subject is allowed to crossover to the other arm. The permanent implant must occur prior to the XXXXXXXX  follow up visit.  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178203] of care. Upon receiving a permanent implant, subjects will continue to participate in the study 
according to Section 6.6. The follow-up timeline will not be reset; the subject will continue with the follow-
up schedule. Subjects are not allowed to crossover more than once. 
 
 Unscheduled Visits 
An unscheduled visit is defined as a visit that occurs between any of the required follow-up visits, such 
as a visit to document a potential or actual adverse event and standard re-programming or therapy 
adjustment visits. Any data collected related to the clinical study endpoints should be documented by 
[CONTACT_847443].  
Following an unscheduled visit, the subject should be seen for the next scheduled study visit within 
window. 
 Schedule of Events  
XXXXXXXX  
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178204] definitions and reporting timelines to be 
used and adhered to by [CONTACT_473].  
 
7.1 Definition 
 Adverse Event 
An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not 
related to the medical device under investigation. 
 
As part of ISO14155 Section 3.2, the Adverse Event definition has the following notes: 
 
Note 1:  This definition includes events related to the medical device under investigation or the 
comparator. 
Note 2:  This definition includes events related to the procedures involved. 
Note 3:  For users or other persons, this definition is restricted to events related to medical devices under 
investigation. 
 Serious Adverse Event 
If the AE meets any of the criteria below, it is regarded as a serious adverse event (SAE).  
 
a) Led to a death 
b) Led to a serious deterioration in health of the subject, that either resulted in  
1. a life-threatening illness or injury, or 
2. a permanent impairment of a body structure or a body function, or 
3. in-patient hospi[INVESTIGATOR_1081], or 
4. medical or surgical intervention to prevent life threatening illness or injury or permanent 
impairment to a body structure or a body function 
5. chronic disease  
c) Led to fetal distress, fetal death or a congenital abnormality or birth defect 
 
Note:  A planned hospi[INVESTIGATOR_272] a pre-existing condition, or a procedure required by [CONTACT_292323] a 
serious deterioration in health, is not considered to be an SAE. 
 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178205] or device under 
investigation caused or contributed to an AE is to be determined by [CONTACT_398794]. Determination should be based on the assessment of temporal relationships, 
evidence of alternative etiology, medical/biologic plausibility and patient condition (pre-existing condition). 
 
 1.1.1      Serious Health Threat 
  
Serious Health Threat is a signal from any adverse event or device deficiency that indicates an imminent 
risk of death or a serious deterioration in the health in subjects, users or other persons, and that requires 
prompt remedial action for other subjects, users or other persons 
Note: This would include events that are of significant and unexpected nature such that they become 
alarming as a potential serious health hazard or possibility of multiple deaths occurring at short intervals. 
 
7.[ADDRESS_1178206] report SAEs to the Sponsor no later than 3 calendar days from the 
day the site personnel became aware of the event or as per the investigative 
site’s local requirements, if the requirement is more stringent than those outlined. 
 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178207] the date the site staff became aware that the event met the criteria of an SAE in the 
source document.  The Investigator will further report the SAE to the local IRB/EC according to the 
institution’s IRB/EC reporting requirements. 
 
Reportable events to the sponsor are considered: 
 All adverse events related to the SCS device and/or SCS procedure regardless of seriousness 
criteria.  
 All serious adverse events including deaths 
 
Refer to the specific device manuals for adverse events associated with the use of SCS systems.  
 
Device deficiencies (DD) are not collected on a DD form in this study. Sites should report all device 
deficiencies/malfunctions to the Sponsor’s Customer Service Department. 
Device deficiency is defined as an inadequacy of a medical device related to its identity, quality, 
durability, reliability, safety or performance, such as malfunction, misuse or use error and inadequate 
labeling. This includes the failure of the device to meet its performance specifications or otherwise 
perform as intended. Note: performance specifications include all claims made in the labeling of the 
device. 
 
If device deficiency does not involve an AE, the investigator must notify the Abbott Post Market Surveillance Department by [CONTACT_847444]. 
 
 Procedure for recording and reporting subject death 
Should death occur, the investigator is requested to record death information in the hospi[INVESTIGATOR_847418]. The death 
events must be reported as per the SAE reporting requirements provided in the “Adverse Events 
Reporting” section 7.3.1. 
 All efforts to obtain the details about the circumstances surrounding the subject death should be 
made by [CONTACT_737]. 
 
The subject’s death, is an outcome of an AE and an early conclusion of the subject’s participation 
in the clinical investigation. Therefore, the Investigator is required to complete the Withdrawal 
form.  
8.0 STATISTICAL CONSIDERATIONS  
The following section describes the statistical methods for the clinical investigation. A separate Statistical 
Analysis Plan (SAP) will provide additional details on statistical analyses, including justification of clinical 
investigation design, sensitivity analyses, poolability analyses, subgroup analyses, and analysis of 
descriptive endpoints, if applicable. 
8.1 Analysis Populations 
The following analysis populations are defined for the study: 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 30 of 48  
 
1. XXXXXXXX .  
 
8.2 Statistical Analyses  
This section describes the analysis for the primary effectiveness endpoint, secondary endpoints, and 
descriptive endpoints. Further details are provided in the Statistical Analysis Plan. 
 
 Primary Endpoint(s) Analyses  
The null and alternative hypotheses for the primary effectiveness endpoint are as follows: 
 
H0: PSCS = P CMM 
 
H1: PSCS ≠ P CMM 
 
 
 
PSCS and P CMM denote the response rate at 6 months for SCS and CMM groups, respectively.   
 
The response rates between the two groups will be compared using XXXXXXXX  at the significance level 
of XXXXXXXX . 
 
 Secondary Endpoint(s) Analyses 
Selected secondary endpoints (e.g., composite responder rate based on NRS or ODI improvements, 
change on ODI from baseline, % change in NRS from baseline) will be compared between the two 
treatment groups. Appropriate statistical methods will be used according to the types of the data. 
Continuous variables may be analyzed using the XXXXXXXX . Binary variables may be analyzed using 
tests such XXXXXXXX . Further details are described in the Statistical Analysis Plan (SAP). 
 Descriptive Endpoint(s) Analyses 
Descriptive summary statistics will be presented for the descriptive endpoints within each treatment 
group. Continuous variables will be summarized using mean, standard deviation, median, minimum, and 
maximum. Categorical variables will be summarized using XXXXXXXX . Time-to-event variables will be 
analyzed using the XXXXXXXX . The 95% confidence intervals for each type of data will be provided as 
appropriate. 
 
Difference between groups will be summarized using descriptive statistics including XXXXXXX . 
8.3 Sample Size/Power Calculation  
The study was designed to enroll approximately XXXXXXXX . The following assumptions are used in the 
power calculation for the primary endpoint: 
 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178208] of missing outcome data. Details will be described in the Statistical Analysis Plan. 
 
8.8 Planned Interim Analysis 
An interim analysis will be performed for sample size re-estimation, XXXXXXXX  is sufficient for meeting 
the study endpoints. This analysis is detailed in the Adaptive Design Plan. 
8.9 Success Criteria  
The study will be considered as successful if the primary effectiveness endpoint is met, i.e., the SCS is 
superior to CMM with regards to the response rate. 
8.10 Deviations from Statistical Plan 
The Sponsor will document any major changes to the statistical plan in an amendment to the statistical 
plan and any less significant changes to the planned analyses in the final report.  
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178209] ACCESS TO SOURCE DATA/DOCUMENTS 
The Investigator/Institution will permit direct access to source data/documents for performing clinical 
investigation-related monitoring, audits, IRB/EC review and regulatory inspections. 
 
Subjects providing informed consent are agreeing to allow clinical investigation monitors or regulatory 
authorities, including foreign countries, to review in confidence any records identifying the subjects in this 
clinical investigation. This information may be shared with regulatory agencies; however, the Sponsor 
undertakes not to otherwise release the subject's personal and private information. 
10.[ADDRESS_1178210] investigators qualified by [CONTACT_404052]. Sites will be selected based upon review of a recent site assessment, if applicable, and the 
qualifications of the investigators who will participate in the clinical investigation. 
10.2 Clinical Investigation Finances and Agreements 
Abbott will finance the clinical investigation and will compensate investigational sites for participation in 
the clinical investigation per the conditions of agreement between Abbott and the investigational site. 
10.3 CIP Amendments  
The Sponsor will provide approved CIP amendments to the Investigators prior to implementing the 
amendment. The Principal Investigator [INVESTIGATOR_179168]/EC or equivalent committee of 
the CIP amendment (administrative changes) or obtaining IRB’s/EC’s approval of the CIP amendment 
(changes in subject care or safety), according to the instructions provided by [CONTACT_404055].   
 
Sites must document in writing acknowledgement/approval of the CIP amendment by [CONTACT_1201]/EC prior to 
implementation of the CIP amendment. Sites must also provide copi[INVESTIGATOR_432601]. 
10.4 Training 
 Site Training 
All Investigators and clinical investigation personnel are required to attend Sponsor training sessions, 
which may be conducted at an Investigator's meeting, a site initiation visit, or other appropriate training 
sessions. Over-the-phone or self-training may take place as required. Training of Investigators and 
clinical investigation personnel will include, but is not limited to, the CIP requirements, investigational 
device usage, electronic case report form completion, clinical investigation personnel responsibilities, 
and site compliance expectations. All Investigators and clinical investigation personnel that are trained 
must sign a training log (or an equivalent) upon completion of the training. Prior to signing the training 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178211] of care at the site.  
10.5 Monitoring  
Sponsor and/or designee will monitor the clinical investigation throughout its duration according to the 
CIP-specific monitoring plan which will include the planned extent of source data verification.  
 
Prior to initiating any procedure, the Sponsor monitor (or delegate) will ensure that the following criteria 
are met:  
 
 The Investigator understands and accepts the obligation to conduct the clinical investigation 
according to the CIP and applicable regulations and has signed the Investigator Agreement or the 
Clinical Trial Agreement. 
 The Investigator and his/her staff should have sufficient time and facilities to conduct the clinical 
investigation and should have access to an adequate number of appropriate subjects to conduct 
the clinical investigation.  
 Sites must have source documentation (including original medical records) to substantiate proper 
informed consent procedures, adherence to CIP procedures, adequate reporting and follow-up of 
adverse events, accuracy of data collected on case report forms, and device information.  
 The Investigator/site will permit access to such records and will maintain a monitoring visit sign-in 
log at the site. The Investigator will agree to dedicate an adequate amount of time to the 
monitoring process. The Investigator and/or research coordinator will be available for monitoring 
visits. It is expected that the Investigator will provide the monitor with a suitable working 
environment for review of clinical investigation-related documents. 
10.[ADDRESS_1178212] report all deviations to the 
Sponsor using the Deviation CRF. The Sponsor will monitor the occurrence of CIP for evaluation of 
investigator compliance to the CIP and regulatory requirements and handle according to written 
procedures. Investigators will inform their IRB/EC or equivalent committee of all CIP deviations in 
accordance with their specific IRB/EC or equivalent committee reporting policies and procedures.  
 
In the event of repeated non-compliance, as determined by [CONTACT_1034], a Sponsor’s monitor or 
company representative will attempt to secure compliance by [CONTACT_10980] (and not 
limited to):  
 Visiting the Investigator and/or delegate 
 Telephoning the Investigator and/or delegate 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 34 of 48  
 
 Corresponding with the Investigator and/or delegate 
 
Repeated non-compliance with the signed agreement, the CIP, or any other conditions of the clinical 
investigation may result in further escalation in accordance with the Sponsor’s written procedures, 
including securing compliance or, at its sole discretion, the Sponsor may terminate the Investigator's 
participation in the clinical investigation.  
 
10.[ADDRESS_1178213] the review of the 
current clinical investigation (e.g., Form FDA 483, Inspectional Observations, Warning Letters, Inspection 
Reports, etc.). The Sponsor may provide any needed assistance in responding to regulatory audits. 
10.[ADDRESS_1178214] audits in accordance with the audit plan and the operating procedures. 
2. Individuals engaged in auditing (hereinafter referred to as "auditor") shall be different than those 
in charge of medical device development or monitoring. 
3. The auditor shall prepare an audit report documenting the matters confirmed in the audit to certify 
and verify that the audit has been conducted and submit them to the Sponsor. 
10.[ADDRESS_1178215] enrollment, general data 
collection and non-compliance with the CIP at individual centers, and to review operational issues that 
may arise and warrant a CIP amendment or other corrective action. 
 Publications Committee  
A Publication Committee may be established to oversee clinical investigations publications, including 
publication planning and authorship determinations. Publication Committee membership may include 
members of the Steering Committee, Principal Investigators, a representative of the Sponsor, and a 
statistician. The Publication Committee will determine policy and strategies regarding individual 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 35 of 48  
 
presentations and/or publications arising from clinical investigation generated data. The committee will 
also review all external requests for accessing clinical investigation-related data and strategies aligning 
with the Sponsor’s presentation and publication team expectations. The committee will also follow the 
Sponsor’s applicable policies and Standard Operating Procedures. 
 Clinical Events Committee (CEC) 
The CEC is an independent adjudication body comprised of qualified physicians who are not participants 
in the clinical investigation. The CEC will review and adjudicate pre-specified events reported by 
[CONTACT_847445].  
11.[ADDRESS_1178216] KEEPI[INVESTIGATOR_432602]/or its affiliates will maintain documentation of the systems and procedures used in data 
collection for the duration of the clinical investigation.  
 
XXXXXXXX .   
 
The data will be subjected to consistency and validation checks within the EDC system and 
supplemental review by [CONTACT_1034].    
 
At the end of the clinical investigation, completed CRF images with the date-and-time stamped electronic 
audit trail indicating the user, the data entered, and any reason for change (if applicable) will be provided 
to the investigational sites, if requested.  
 
For the duration of the clinical investigation, the Investigator will maintain complete and accurate 
documentation including, but not limited to, medical records, clinical investigation progress records, 
laboratory reports, CRFs, signed ICFs, device accountability records (if applicable), correspondence with 
the IRB/EC and clinical investigation monitor/Sponsor, adverse event reports, and information regarding 
subject discontinuation or completion of the clinical investigation. 
11.1 Protection of Personally Identifiable Information 
The Sponsor respects and protects personally identifiable information collected or maintained for this 
clinical investigation.  
 
The Sponsor implements technical and physical access controls to ensure  Personal Information is 
accessible only to and processed only on a ‘need to know’ basis, including periodic review of access 
rights, and revocation of access when an individual’s employment is terminated or the individual 
transitions to a role that does not require access to Personal Information, and appropriate restrictions on 
physical access to premises, facilities, equipment, and records containing Personal Information. 
 
The Sponsor requires the investigational sites to enter only pseudonymous Personal Information (key-
coded) necessary to conduct the clinical investigation, such as the patient’s medical condition, treatment, 
dates of treatment, etc., into Sponsor’s data management systems. The Sponsor discloses as part of the 
clinical investigation informed consent process that some Sponsor representatives still may see Personal 
Information at the participating sites for technical support of the participating physicians on the device 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178217] and confidentiality of his/her information. 
 
The Sponsor data management systems  and processes were designed, developed, and tested 
according to industry standards to appropriately safeguard Confidential Information (including any 
Personal Information) against unauthorized access and/or interference by [CONTACT_26404], intrusion, theft, 
destruction, loss or alteration. Clinical Investigation data are encrypted in transit and at rest.  
 
The Sponsor maintains a Privacy Incident  procedure that complies in all respects with Applicable Law 
and industry best practices. 
11.2 Data Management Plan 
A Data Management Plan (DMP) will describe procedures used for data review, data cleaning, and 
issuing and resolving data discrepancies. If appropriate, the Sponsor may update the DMP throughout 
the duration of the clinical investigation. The Sponsor will track and document control all revisions. 
11.[ADDRESS_1178218]’s original medical 
records that corroborates data collected on the CRFs. To comply with these regulatory 
requirements/GCP, sites should include the following information in the subject record at a minimum and 
if applicable to the clinical investigation: 
 Medical history/physical condition of the subject before involvement in the clinical investigation 
sufficient to verify CIP entry criteria 
 Dated and signed notes on the day of entry into the clinical investigation referencing the Sponsor, 
CIP number, subject ID number, and a statement that informed consent was obtained 
 Dated and signed notes from each subject visit (for specific results of procedures and exams) 
 
 Notes regarding CIP-required and prescription medications taken during the clinical investigation 
(including start and stop dates) 
 Subject’s condition upon completion of or withdrawal from the clinical investigation 
 Any other data required to substantiate data entered into the CRF 
 Patient reported outcome measures may be completed using CRF worksheets. This serves as 
source documentation. 
 Patient reported outcome measures may be completed by [CONTACT_847446]-Q 
application. The electronic CRF output will serve as source documentation.  
 Adverse events reported and their resolution, including supporting documents, such as discharge 
summaries, consult reports, office notes, x-ray results, lab results and other source documents as 
applicable per the reported AE. The documentation of site awareness of SAEs and of investigator 
assessment of device relationship for SAEs should be included. 
 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 37 of 48  
 
11.4 Case Report Form Completion  
Site research personnel trained on the CIP and CRF completion will perform the primary data collection 
clearly and accurately based on source-documented hospi[INVESTIGATOR_3491]/or clinic chart reviews. The Investigator 
will ensure accuracy, completeness, legibility, and timeliness of the data reported to the Sponsor on the 
CRFs and in all required reports. 
 
Sites will collect data on all subjects enrolled into the clinical investigation.   
XXXXXXXX  
11.[ADDRESS_1178219] Retention 
The Sponsor and Investigator/Site will archive and retain all documents pertaining to the clinical 
investigation as per the applicable regulatory record retention requirements. The Investigator must obtain 
permission from Sponsor in writing before destroying or transferring control of any clinical investigation 
records. 
12.[ADDRESS_1178220]/Medical Ethics Committee Review and Approval 
The Principal Investigator [INVESTIGATOR_458045]/EC approval for the CIP and 
ICF/other written information provided to the patient prior to consenting and enrolling patients in this 
clinical investigation. The site must receive the approval letter prior to the start of this clinical 
investigation and provide a copy to the Sponsor.  
 
Sites will submit any amendments to the CIP as well as associated ICF changes to the IRB/EC and 
written approval obtained prior to implementation, according to each institution’s IRB/EC requirements.  
 
No changes will be made to the CIP or ICF or other written information provided to the patient without 
appropriate approvals, including IRB/EC, the Sponsor, and the regulatory agencies (if applicable).  
 
Until the clinical investigation is completed, the Investigator will advise his/her IRB/EC of the progress of 
this clinical investigation, per IRB/EC requirements. Written approval must be obtained from the IRB/EC 
yearly to continue the clinical investigation, or according to each institution’s IRB/EC requirements.  
 
Sites will not perform any investigative procedures, other than those defined in this CIP, on the enrolled 
subjects without the written agreement of the IRB/EC and the Sponsor. 
13.0 CLINICAL INVESTIGATION CONCLUSION 
The clinical investigation will be concluded when: 
 All sites are closed AND 
 The final report has been provided to Investigators or the Sponsor has provided formal 
documentation of clinical investigation closure.  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178221] review and approve any proposals for 
publications or presentations by [CONTACT_83196] a timely manner in compliance with the Sponsor’s 
publication policy set forth in the Clinical Trial Agreement. 
 
The Sponsor will be responsible for determining whether to register the clinical investigation on 
www.clinicaltrials.gov or any other clinical trials, in accordance with the International Committee of 
Medical Journal Editors guidelines, or any other applicable guidelines. In the event the Sponsor 
determines that the clinical investigation should be registered, the Sponsor shall be responsible for any 
such registration and results posting as required by [CONTACT_26149].gov website. Institution and/or 
Principal Investigator(s) shall not take any action to register the clinical investigation.  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 39 of 48  
 
15.0 RISK ANALYSIS 
15.1 Anticipated Clinical Benefits 
Published literature on current treatment options for patients with chronic, intractable, low back pain 
report mild, if any, improvements in pain and physical function. XXXXXXXX . A recent review of opi[INVESTIGATOR_847419], 
non-opi[INVESTIGATOR_847420] a statistically significant greater reduction. Furthermore, 
improvements in pain relief are outweighed by [CONTACT_847447][INVESTIGATOR_2438] (30). Deterioration in 
functional outcomes has also been associated with opi[INVESTIGATOR_847421] (31). 
In contrast, small case series report significant improvements in pain and function using various spi[INVESTIGATOR_847422] (19, 32). On average, pain is reduced by [CONTACT_46431] 70% and 
disability is reduced to a minimal level (average ODI < 20%). These small studies provide support for 
investigating the effect of SCS in this population. In addition, the unique mechanism of action of BurstDR 
provides the ability to evaluate improvement in psychometric measures.  
15.2 Foreseeable Adverse Events and Anticipated Adverse Device Effects 
The use of a neurostimulation system involves risks. In addition to the risks commonly associated with 
surgery, below are listed the anticipated potential adverse effects with the use of a neurostimulation 
system: 
 
XXXXXXXX  
15.3 Residual Risks Associated with the Device Under Investigation, as Identified in the 
Risk Management Report / Risk Analysis Report 
The clinical risks associated with Abbott’s spi[INVESTIGATOR_847423]. Any potential 
residual risks are considered outweighed by [CONTACT_111333], and the overall residual risk was determined to 
be acceptable. Clinical evidence demonstrates acceptable safety and performance of the device under 
this post-market study.  
15.[ADDRESS_1178222] a sufficient level of clinical expertise, investigator selection, and appropriate training for all involved 
in the study activities. In-depth recommendations, special precautions and instructions regarding [patient 
selection, device handling, device placement and system removal] are included in IFU documents of all 
devices included in this study. All device-related adverse events and device deficiencies will be reported 
to the Sponsor and will be monitored internally for safety surveillance purposes. 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 40 of 48  
 
15.6 Risk to Benefit Rationale 
The risks associated with Abbott’s neurostimulation systems are anticipated to be comparable to those 
associated with the use of other commercially available neurostimulation systems. The patients 
participating in this study are indicated for using a neurostimulation system as part of their standard 
medical management and are subject to the risks associated with these devices.   
 
 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 41 of 48  
 
APPENDIX I: ABBREVIATIONS AND ACRONYMS 
AE Adverse Event 
CEC  Clinical Events Committee  
CIP Clinical Investigation Plan  
CLBP Chronic Low Back Pain 
CMM  Conventional  Medical Management  
CRF Case Report Form 
CT Computed Tomography  
DMP Data Management Plan 
EC Ethics Committee  
ECG  Electrocardiogram  
EDC Electronic Data Capture 
FAS Full Analysis Set  
FDA U.S. Food and Drug Administration 
GCP  Good Clinical Practice  
HIPPA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
IFU Instructions for Use  
IRB Institutional Review Board 
MCID  Minimal Clinically Important Difference  
MHRA Medicines and Healthcare Products Regulatory Agency 
MME  Morphine Milligram Equivalents  
MRI Magnetic Resonance Imaging  
NRS Numerical Rating Scale 
ODI Oswestry Disability index  
PCS Pain Catastrophizing Scale 
PGIC  Patient Global Impression of Change  
PRO Patient Reported Outcome 
PROMIS  Patient -Reported Outcomes Measurement Information System  
SAE  Serious Adverse Event  
SCS Spi[INVESTIGATOR_847424]-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 42 of 48  
 
APPENDIX II: DEFINITIONS 
APPENDIX III: SITE CONTACT [CONTACT_847448] a separate cover by 
[CONTACT_847449]: 
 
APPENDIX IV: LITERATURE REVIEW 
 
APPENDIX VI: LABELS 
XXXXXXXX  
APPENDIX VII: CASE REPORT FORMS 
Final (draft) CRFs will be provided under a separate cover. 
 
APPENDIX VIII: INFORMED CONSENT FORM 
A template informed consent form will be provided under a separate cover.  
 
 
APPENDIX IX: MONITORING PLAN 
A copy of the Monitoring Plan can be obtained upon request from the Sponsor Clinical Project Manager 
for the clinical investigation. 
 
APPENDIX XI: REVISION HISTORY 
This CIP may be amended as appropriate by [CONTACT_1034]. Rationale will be included with each amended 
version in the revision history table below. The version number and date of amendments will be 
documented. 
 
IRB/EC and relevant Regulatory Authorities, if applicable, will be notified of amendments to the CIP. 
 XXXXXXXX  
 
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 43 of 48  
 
APPENDIX XII: CIP SUMMARY 
Clinical 
Investigation 
Name [CONTACT_834543]_988 DISTINCT 
Title Dorsal spI[INVESTIGATOR_847425](s) The objective of this study is to evaluate the efficacy of BurstDRTM spi[INVESTIGATOR_287197], compared with conventional medical management, in improving 
pain and back pain-related physical function in patients suffering with chronic, 
refractory axial low back pain, who have not had lumbar spi[INVESTIGATOR_847409].   
Device Under 
Investigation  BurstDRTM capable products 
Number of 
Subjects Required 
for Inclusion in 
Clinical Investigation  The study will enroll up to 270 patients at up to 30 US sites. 
Clinical 
Investigation 
Design  This is a prospective, randomized, controlled, clinical trial 
Primary 
Endpoint(s) The primary effectiveness endpoint is the difference in responders between 
groups at [ADDRESS_1178223] is considered a responder for the primary 
endpoint if the following criteria are met: 
 Improvement in pain, defined as a ≥ 50% decrease on NRS   
Subject Follow-up  XXXXXXXX  
Inclusion Criteria 1. Patient must be willing and able to provide written informed consent 
prior to any clinical investigation-related procedure. 
2. Age ≥ 18 years  
3. Patient has chronic (at least 6 months), refractory axial low back pain 
with a neuropathic component and is not a candidate for spi[INVESTIGATOR_79477] 
4. Patient has back pain for ≥ [ADDRESS_1178224] stimulation  
7. Low back pain ≥ 6 on Numerical Rating Scale 
8. Oswestry Disability Index score of ≥ 30% 
Willing and able to comply with the instructions for use, operate the 
study device, and comply with this Clinical Investigation Plan  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178225] 12 months 
that is clearly identified and is likely the cause of the CLBP, that can be 
addressed with surgery. 
2. Primary complaint of leg pain, or leg pain is greater than back pain 
3. Back pain is due to any of the following:  
 spi[INVESTIGATOR_847411] > 2 mm translation on radiographic 
imaging 
 visceral causes (e.g., endometriosis or fibroids)  
 vascular causes (e.g., aortic aneurysm)  
 spi[INVESTIGATOR_158394] (e.g., osteomyelitis)  
 inflammation or damage to the spi[INVESTIGATOR_1831] (e.g. arachnoiditis or 
syringomyelia) 
 tumor or spi[INVESTIGATOR_158308] 
 
4. Has widespread pain (e.g. fibromyalgia) or pain in other area(s), not 
intended to be treated in this study (e.g. neck pain, shoulder pain) 
5. Patient has seronegative spondyloarthropathy (e.g. rheumatoid, lupus, 
psoriatic) 
6. Neurological deficit (e.g. foot drop) 
7. Prior lumbar spi[INVESTIGATOR_847412] 
8. Patient has used a morphine equivalent daily dose of more than [ADDRESS_1178226] 30 days  
9. Patient is bed bound 
10. Patients with regular intake of systemic steroids (except inhaled steroids 
used to treat asthma) 
11. Imaging (MRI, CT, X-ray) findings within the last 12 months that 
contraindicates lead placement  
12. Known allergic reaction to implanted materials 
13. Severe scoliotic deformity (>11 degrees in thoracic or lumbar spi[INVESTIGATOR_050]) 
14. Patient has a history of, or existing intrathecal drug pump 
15. Patient has previous experience with neuromodulation devices, 
including a failed trial 
16. BMI > 40 
17. Patient is enrolled, or intends to participate, in another clinical drug 
and/or device study or registry that may interfere with the results of this 
study, as determined by [CONTACT_847438] 
18. Presence of other anatomic or comorbid conditions, or other medical, 
social, or psychological conditions that, in the investigator’s opi[INVESTIGATOR_1649], 
could limit the subject’s ability to participate in the clinical investigation 
or to comply with follow-up requirements of the clinical investigation 
results. 
19. Failed psychological evaluation  
20. Suspi[INVESTIGATOR_847413], substance abuse, or 
drug-seeking behavior 
21. Patient demonstrated 2 or more Waddell’s signs of nonorganic behavior  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 45 of 48  
 
22. Patient is in current litigation for back pain/injury, or is currently receiving 
worker’s compensation 
23. Pregnant or nursing subjects and those who plan pregnancy during the 
clinical investigation follow-up period.  
 Female subjects of child-bearing potential must have a negative 
pregnancy test done within 7 days prior to enrollment/baseline 
visit per site standard test. 
 
 
 
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 46 of 48  
 
APPENDIX XIII: EXCEPTIONS FROM ISO [ZIP_CODE] COMPLIANCE 
 
Minimal exceptions to ISO [ZIP_CODE]:[ADDRESS_1178227] 
the safety and protection of the clinical investigation subjects and do not compromise data quality and 
security. 
 
 This clinical investigation provides market approved devices, which will be used within their 
intended purpose, thus clinical investigation labelling will not be applied, a separate investigator 
Brochure will not be created, and clinical device accountability will not be set up. 
 The study will not be submitted for review to the Competent Authority, only standard vigilance 
reporting will be observed. Local and/or regional requirements might be still applicable and will be 
tracked in a study specific Safety Plan. 
 Financial disclosures will not be collected from the Investigators. 
 
 
 
  
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page 47 of 48  
 
REFERENCES 
 
1. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global 
prevalence of low back pain. Arthritis Rheum. 2012;64(6):2028-37. 
2. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and 
national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 
countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 
2017;390([ZIP_CODE]):1211-59. 
3. Shmagel A, Foley R, Ibrahim H. Epi[INVESTIGATOR_131165]: Data From 
the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 
2016;68(11):1688-94. 
4. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and 
years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic 
analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390([ZIP_CODE]):1211-59. 
5. Fritzell P, Hagg O, Wessberg P, Nordwall A, Swedish Lumbar Spi[INVESTIGATOR_847426] G. [ADDRESS_1178228] 
Winner in Clinical Studies: Lumbar fusion versus nonsurgical treatment for chronic low back pain: a 
multicenter randomized controlled trial from the Swedish Lumbar Spi[INVESTIGATOR_158472]. Spi[INVESTIGATOR_050] (Phila Pa 
1976). 2001;26(23):2521-32; discussion 32-4. 
6. Phillips FM, Slosar PJ, Youssef JA, Andersson G, Papatheofanis F. Lumbar spi[INVESTIGATOR_847427]: a systematic review. Spi[INVESTIGATOR_050] (Phila Pa 1976). 
2013;38(7):E409-22. 
7. Manchikanti L, Hirsch JA. An update on the management of chronic lumbar discogenic pain. Pain 
Manag. 2015;5(5):373-86. 
8. Kumar K, North R, Taylor R, Sculpher M, Van den Abeele C, Gehring M, et al. Spi[INVESTIGATOR_847428]. Conventional Medical Management: A Prospective, Randomized, Controlled, Multicenter 
Study of Patients with Failed Back Surgery Syndrome (PROCESS Study). Neuromodulation. 
2005;8(4):213-8. 
9. Rajaee SS, Bae HW, Kanim LE, Delamarter RB. Spi[INVESTIGATOR_847429]: analysis of 
trends from 1998 to 2008. Spi[INVESTIGATOR_050] (Phila Pa 1976). 2012;37(1):67-76. 
10. Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, et al. US Health Care Spending by [CONTACT_847450], 1996-2016. JAMA. 2020;323(9):863-84. 
11. McGirt MJ, By[CONTACT_459981] M, Archer KR, Devin CJ, Chotai S, Parker SL, et al. An analysis from the 
Quality Outcomes Database, Part 1. Disability, quality of life, and pain outcomes following lumbar spi[INVESTIGATOR_84017]: predicting likely individual patient outcomes for shared decision-making. J Neurosurg Spi[INVESTIGATOR_050]. 
2017;27(4):357-69. 
12. Vallejo R, Bradley K, Kapural L. Spi[INVESTIGATOR_847430]: Mode of Action. Spi[INVESTIGATOR_050] 
(Phila Pa 1976). 2017;[ADDRESS_1178229] 14:S53-S60. 
13. Meyerson BA, Linderoth B. Mode of action of spi[INVESTIGATOR_847431]. J Pain 
Symptom Manage. 2006;31([ADDRESS_1178230]):S6-12. 
14. Ahmed S, Yearwood T, De Ridder D, Vanneste S. Burst and high frequency stimulation: 
underlying mechanism of action. Expert Rev Med Devices. 2018;15(1):61-70. 
15. Deer TR, Campos LW, Pope JE. Evaluation of Abbott's BurstDR stimulation device for the 
treatment of chronic pain. Expert Rev Med Devices. 2017;14(6):417-22. 
16. Hunter CW, Sayed D, Lubenow T, Davis T, Carlson J, Rowe J, et al. DRG FOCUS: A Multicenter 
Study Evaluating Dorsal Root Ganglion Stimulation and Predictors for Trial Success. Neuromodulation. 
2019;22(1):61-79. 
 ABT-CIP-[ZIP_CODE] Ver. XX  
Study Name: [CONTACT_847451] (CRD_988)  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: XXXXXXXX   Page [ADDRESS_1178231] 
stimulation for predominant back pain in failed back surgery syndrome patients: a multicenter 
randomized controlled trial. Pain. 2019;160(6):1410-20. 
18. North RB, Kidd DH, Farrokhi F, Pi[INVESTIGATOR_847432]. Spi[INVESTIGATOR_847433]: a randomized, controlled trial. Neurosurgery. 2005;56(1):98-
106; discussion -7. 
19. Al-Kaisy A, Palmisani S, Smith TE, Pang D, Lam K, Burgoyne W, et al. [ADDRESS_1178232] Stimulation for Chronic Axial Low Back Pain in Patients With No History of Spi[INVESTIGATOR_404897]: A 
Preliminary, Prospective, Open Label and Proof-of-Concept Study. Neuromodulation. 2017;20(1):63-70. 
20. Hoelscher C, Riley J, Wu C, Sharan A. Cost-Effectiveness Data Regarding Spi[INVESTIGATOR_847434]. Spi[INVESTIGATOR_050] (Phila Pa 1976). 2017;[ADDRESS_1178233] 14:S72-s9. 
21. De Ridder D, Vanneste S, Plazier M, Vancamp T. Mimicking the brain: evaluation of St Jude 
Medical's Prodigy Chronic Pain System with Burst Technology. Expert Rev Med Devices. 
2015;12(2):143-50. 
22. Deer T, Slavin KV, Amirdelfan K, North RB, Burton AW, Yearwood TL, et al. Success Using 
Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized 
Controlled Trial Using a Novel Burst Waveform. Neuromodulation. 2018;21(1):56-66. 
23. Amirfeyz R, Pentlow A, Foote J, Leslie I. Assessing the clinical significance of change scores 
following carpal tunnel surgery. Int Orthop. 2009;33(1):181-5. 
24. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective 
outcome measures. J Manipulative Physiol Ther. 2004;27(1):26-35. 
25. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to 
identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911-20. 
26. Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability 
questionnaire. Physiotherapy. 1980;66(8):271-3. 
27. Copay AG, Glassman SD, Subach BR, Berven S, Schuler TC, Carreon LY. Minimum clinically 
important difference in lumbar spi[INVESTIGATOR_158468]: a choice of methods using the Oswestry Disability 
Index, Medical Outcomes Study questionnaire Short Form 36, and pain scales. Spi[INVESTIGATOR_050] J. 2008;8(6):968-
74. 
28. Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L. The Pain 
Catastrophizing Scale: further psychometric evaluation with adult samples. J Behav Med. 
2000;23(4):351-65. 
29. Scott W, Wideman TH, Sullivan MJ. Clinically meaningful scores on pain catastrophizing before 
and after multidisciplinary rehabilitation: a prospective study of individuals with subacute pain after 
whiplash injury. Clin J Pain. 2014;30(3):183-90. 
30. Tucker HR, Scaff K, McCloud T, Carlomagno K, Daly K, Garcia A, et al. Harms and benefits of 
opi[INVESTIGATOR_847435]-surgical acute and chronic low back pain: a systematic review. Br J 
Sports Med. 2019. 
31. Ashworth J, Green DJ, Dunn KM, Jordan KP. Opi[INVESTIGATOR_847436]: Is opi[INVESTIGATOR_847437] 6-month follow-up? Pain. 2013;154(7):1038-44. 
32. Kallewaard JW, Edelbroek C, Terheggen M, Raza A, Geurts JW. A Prospective Study of Dorsal 
Root Ganglion Stimulation for Non-Operated Discogenic Low Back Pain. Neuromodulation. 2019. 
 